Search Result

Results for "

motor activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Receptor (1) Apoptosis (3) Autophagy (2) Dopamine Receptor (1) Dopamine Transporter (1) Eukaryotic Initiation Factor (eIF) (1) Fungal (1) Hedgehog (1) HSP (1) Kinesin (5) mAChR (1) mGluR (1) Necroptosis (2) Neurokinin Receptor (1) Parasite (1) Potassium Channel (2) Serotonin Transporter (1) Sigma Receptor (1)
By Research Areas:	Cancer (6) Infection (2) Metabolic Disease (4) Neurological Disease (15)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18596

SB-215505	5-HT Receptor	Neurological Disease
SB-215505 is a potent and subtype-selective 5-HT_2B receptor antagonist with pK_i values of 8.3, 6.77, 7.66 for 5-HT_2B, 5-HT_2A, 5-HT_2C, respectively . SB-215505 increases wakefulness and motor activity in rats .

HY-19530

PF-2771	Kinesin	Cancer
PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor, inhibiting CENP-E motor activity with an IC₅₀ of 16.1 nM; PF-2771 is used as an anticancer agent.

HY-10299

GSK-923295 Maximum Cited Publications 34 Publications Verification	Kinesin Apoptosis	Cancer
GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with K_i of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.

HY-19005

GYKI-32887	Dopamine Receptor	Neurological Disease
GYKI-32887 is a dopaminergic agonist that can reduce the motor activity levels in rats .

HY-136961

NK 1971 NK266 orotate	Fungal	Infection
NK 1971 (NK266 orotate) is a derivative of NK266 and shows potential antifungal activity. NK 1971 may result in decreased motor skills and seizures in animals .

HY-114909

TachypleginA	Parasite	Infection
TachypleginA can inhibit the motility of T. gondii by binding directly and covalently to C58 of TgMLC1，thereby causing a decrease in the activity of the parasite's myosin motor .

HY-122133

CI 750	Others	Metabolic Disease
CI 750 is a potent and orally active antidiarrheal agent. CI 750 increases the motor pattern of the gastrointestinal tract. CI 750 shows a constipating activity. CI 750 shows no analgesic, addiction liability, or anticholinergic pharmacological activity .

HY-124406

A-794282	Others	Others
A-794282 is a compound with analgesic activity and is a selective mGlu1 receptor antagonist that significantly reduces pain behaviors in a postoperative pain model, but motor side effects may occur at higher doses.

HY-119407

Terpendole E	Kinesin	Cancer
Terpendole E is a mitotic kinesin Eg5 inhibitor. Terpendole E inhibits both motor and microtubule-stimulated ATPase activities of human Eg5. Terpendole E induces formation of a monoastral spindle in M phase .

HY-118406A

Ethybenztropine hydrochloride Ponalid hydrochloride; UK 738 hydrochloride	mAChR	Neurological Disease
Ethybenztropine hydrochloride (Ponalid hydrochloride) is an anticholinergic drug with antiparkinsonian activity. Ethybenztropine hydrochloride may also have dopamine reuptake inhibitory effects. Ethybenztropine hydrochloride is used to improve motor symptoms in patients with Parkinson's disease. Ethybenztropine hydrochloride exerts its inhibitory effects by regulating the balance of neurotransmitters .

HY-14149

Cisapride 1 Publications Verification R 51619; (±)-Cisaprid	5-HT Receptor Potassium Channel	Neurological Disease
Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-122632

Ciliobrevin D 3 Publications Verification	Hedgehog	Cancer
Ciliobrevin D is a cell-permeable, reversible and specific inhibitor of AAA+ ATPase motor cytoplasmic dynein. Ciliobrevin D inhibits Hedgehog (Hh) signaling and primary cilia formation. Ciliobrevin D inhibits dynein-dependent microtubule gliding and ATPase activity in vitro .

HY-N11128

Solidagonic acid	Kinesin	Cancer
Solidagonic acid inhibits HSET motor activity by promoting the conversion from abnormal monopolar to bipolar spindles. Solidagonic acid suppresses fission yeast cell death and enables reversion of the mitotic spindles from a monopolar to bipolar morphology. Solidagonic acid showed the growth inhibitory activity on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam .

HY-115467

MitoBloCK-10 2 Publications Verification	HSP	Metabolic Disease
MitoBloCK-10 (MB-10) is the first small molecule modulator to attenuate *protein-associated motor* (PAM) complex** activity. MitoBloCK-10 (MB-10) inhibits Tim44 (C-terminal domain) binding to the precursor and to Hsp70 .

HY-136281

DuP 734	Sigma Receptor	Neurological Disease
DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT2 receptor ligand with weak affinity for D2 receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics .

HY-14149R

Cisapride (Standard)	5-HT Receptor Potassium Channel	Neurological Disease
Cisapride (Standard) is the analytical standard of Cisapride. This product is intended for research and analytical applications. Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-14149A

Cisapride monohydrate R 51619 monohydrate; (±)-Cisaprid monohydrate	5-HT Receptor	Neurological Disease Metabolic Disease
Cisapride monohydrate is an orally and potent 5-HT₄ receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .

HY-16062

ARQ 621	Kinesin	Cancer
ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity . ARQ 621 is a kinesin inhibitor . ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163978

YGZ-331	Adenosine Receptor	Neurological Disease
YGZ-331 is a sedative with a calming effect. YGZ-331 is a derivative of the adenosine nucleoside NGBA, which can increase GABA levels. YGZ-331 exerts a sedative-hypnotic effect by activating A1R and A2aR, and inhibiting CaMKII phosphorylation (pCaMKII) levels. YGZ-331 can reduce the spontaneous motor activity of mice .

HY-B0863

Glyphosate	Apoptosis Autophagy Necroptosis	Neurological Disease
Glyphosate, a non-selective systemic biocide with broad-spectrum activity, is an herbicidal derivative of the amino acid glycine. Glyphosate inhibits the enzymatic activity of the 5-endopyruvylshikimate 3-phosphate synthase (EPSPS) in the shikimic acid pathway, preventing the synthesis of the aromatic amino acids tyrosine, phenylalanine, and tryptophan. Glyphosate induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, processes that lead to neuronal death by autophagia, necrosis, or apoptosis, as well as the appearance of behavioral and motor disorders .

HY-B0824A

(1R)-cis-Bifenthrin	Others	Others
(1R)-cis-Bifenthrin is a widely used pyrethroid pesticide with activity that reduces motor coordination. (1R)-cis-Bifenthrin has a significant impact on the motor function of ParK_in-/- mice, as shown by increased pole climbing time and wheel running Time decreases. Exposure of (1R)-cis-Bifenthrin resulted in a significant reduction in tyrosine hydroxylase-positive cell counts and protein expression. (1R)-cis-Bifenthrin caused increased expression of mitophagy-related proteins LC3B and p62. (1R)-cis-Bifenthrin has a lower binding energy with transferrin and transferrin receptor 2, showing stronger interactions. The biological effects of (1R)-cis-Bifenthrin show relationships with mitophagy and ferroptosis-related pathways .

HY-117512

UWA-101 hydrochloride	Dopamine Transporter Serotonin Transporter	Neurological Disease
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC₅₀ values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .

HY-B0863B

Glyphosate isopropylammonium	Apoptosis Autophagy Necroptosis	Neurological Disease
Glyphosate isopropylammonium, a non-selective systemic biocide with broad-spectrum activity, is an herbicidal derivative of the amino acid glycine. Glyphosate isopropylammonium inhibits the enzymatic activity of the 5-endopyruvylshikimate 3-phosphate synthase (EPSPS) in the shikimic acid pathway, preventing the synthesis of the aromatic amino acids tyrosine, phenylalanine, and tryptophan. Glyphosate isopropylammonium induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, processes that lead to neuronal death by autophagia, necrosis, or apoptosis, as well as the appearance of behavioral and motor disorders .

HY-149555

DNL343	Eukaryotic Initiation Factor (eIF)	Neurological Disease
DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .

HY-118285

Ro4491533	mGluR	Neurological Disease
Ro4491533 is a selective, negative allosteric mGluR2/3 receptor modulator that is equally effective on both subtypes. Ro4491533 can completely block glutamate-induced calcium mobilization and glutamate-induced [35S]GTPγS binding accumulation. Ro4491533 has good pharmacokinetic properties in mice and rats, high oral bioavailability, and can pass through the blood-brain barrier. Ro4491533 can also reverse the motor inhibition effect of LY379268 in mice and show antidepressant activity in the forced swim test and tail suspension test.

HY-115860

TAS-4	Others	Neurological Disease
TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Others Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library	1,438 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD. MCE offers a unique collection of 1,438 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Anti-Parkinson's Disease Compound Library

1,438 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,438 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library	2,364 compounds
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour. MCE offers a unique collection of 2,364 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Neurodegenerative Disease-related Compound Library

2,364 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,364 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1245

Neuropeptide SF (human) Neuropeptide NPFF (human)	Peptides	Others
Neuropeptide SF human augments paraventricular corticotrophin-releasing hormone (CRH) release and increases adrenocorticotropic hormone (ACTH) and corticosterone levels in the plasma. Neuropeptide SF human play a physiologic role in the regulation of such circadian functions as the activity of motor centers and the HPA axis, through the release of CRH .